Financials data is unavailable for this security.
View more
Year on year Kobayashi Pharmaceutical Co Ltd 's net income deteriorated -63.68% from 10.07bn to 3.66bn despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales).
| Gross margin | 51.11% |
|---|---|
| Net profit margin | 2.21% |
| Operating margin | -2.10% |
| Return on assets | 1.35% |
|---|---|
| Return on equity | 1.72% |
| Return on investment | 1.69% |
More ▼
Cash flow in JPYView more
In 2025, Kobayashi Pharmaceutical Co Ltd increased its cash reserves by 40.72%, or 18.72bn. The company earned 25.59bn from its operations for a Cash Flow Margin of 15.44%. In addition the company used 154.00m on investing activities and also paid 7.92bn in financing cash flows.
| Cash flow per share | 166.88 |
|---|---|
| Price/Cash flow per share | 35.32 |
| Book value per share | 2,838.34 |
|---|---|
| Tangible book value per share | 2,604.09 |
More ▼
Balance sheet in JPYView more
| Current ratio | 2.47 |
|---|---|
| Quick ratio | 2.10 |
| Total debt/total equity | 0.0032 |
|---|---|
| Total debt/total capital | 0.0032 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share increased 1.96% while earnings per share excluding extraordinary items fell by -63.68%. The positive trend in dividend payments is noteworthy since only some companies in the Personal & Household Prods. industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 1.31% |
|---|---|
| Div growth rate (5 year) | 6.20% |
| Payout ratio (TTM) | 89.44% |
| EPS growth(5 years) | -27.51 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -63.68 |
More ▼
